A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Metoclopramide (GIMOTI)

Dopamine-2 Receptor Antagonist class · 10 generic manufacturers · 15 ANDAs filed at FDA.

First FDA approval1990-09-30
Generic availableYes · 10 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$20.1M in CY2024 Part D spend1.6M claims · 670K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.039/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.042
Across all dosage forms in distribution.
Highest NADAC
$0.046
Range is tight.
Plans with PA
1 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Metoclopramide used for?

Metoclopramide is a Dopamine-2 Receptor Antagonist medication tracked in Medicare Part D.

Is there a generic for Metoclopramide?

Yes. 15 ANDAs filed at FDA, 10 generic manufacturers currently shipping.

How much does my plan pay for Metoclopramide?

Across 329 Part D plans, Metoclopramide averages $0.042/unit (NADAC). Lowest available: $0.039/unit. Highest in distribution: $0.046/unit.

Is Metoclopramide on the FDA shortage list?

No. Metoclopramide is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Dopamine-2 Receptor Antagonist2 alternatives in D1
01
Amisulpride
Brand: Barhemsys
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Droperidol
Dopamine-2 Receptor Antagonist
Lowest NADAC
2Generic mfrs
$987CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.